Press Releases & News

SAN DIEGO– (BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of COL (retired) George E. Peoples, MD, FACS to its Scientific and Medical Advisory Board.   Dr. Peoples has served his…

SAN DIEGO– (BUSINESS WIRE)– Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, Heehyoung Lee, Managing Partner at LumeBio, to its board of directors. Dr. Lee brings over 15…

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, presented pre-clinical data on their lead oncolytic virus candidate SNV1 (allogeneic adipose derived mesenchymal stem cells loaded with tumor selective CAL1 vaccinia virus) in a poster…

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced the acceptance of an abstract for presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium, which is being held February 6  to February 8, 2020, at the Rosen…

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced Series A investments from two South Korean firms to advance manufacturing in preparation for Calidi's pre-IND and IND filings. The investment efforts were led…

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that the CEO of Calidi Biotherapeutics, Allan Camaisa, received the Pillars of Hope Award by the Mitchell Thorp Foundation.…

SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George Ng, Partner of PENG Life Science Ventures. His extensive background includes co-founding and leading the efforts of…

SAN DIEGO, CA / ACCESSWIRE / September 18, 2019 / Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced that they were named one of the "50 Most Trustworthy Companies of the Year" for 2019 by The Silicon Review magazine.…

SAN DIEGO, CA / ACCESSWIRE / August 29, 2019 / Calidi Biotherapeutics Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer announced today, the completion of the adipose tissue collection from healthy donors necessary for isolation of adipose-derived mesenchymal stem cells (AD-MSC) -…

Calidi Biotherapeutics, Inc., a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of a distinguished innovator in the field of cancer diagnosis and treatment, Ewa Carrier, MD, to their medical and scientific advisory board. Dr. Carrier has…